Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Status: ENROLLING_BY_INVITATION
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Ovarian Cancer|Breast Neoplasms|Ovarian Neoplasms|BRCA Mutation|HER2-positive Breast Cancer|HER2-negative Breast Cancer|HER-2 Protein Overexpression
Interventions: DRUG: Axitinib
Sponsor: Lynkcell Europe